Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (11-20 of 436) with videos related to

Pageof 44
Sort By:
Cancer Journal (Sudbury, Mass.)|April 26, 2016
Immune Checkpoint Therapy in Renal Cell CarcinomaChung-Han Lee, Robert J Motzer
Urologic Oncology|December 4, 2014
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinomaChung-Han Lee, Robert J Motzer
Nature Reviews. Nephrology|January 20, 2017
Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancerChung-Han Lee, Robert J Motzer
The New England Journal of Medicine|April 17, 2024
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New ChallengesMartin H Voss, Robert J Motzer
Seminars in Urologic Oncology|December 19, 2002
Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumorsG Varuni Kondagunta, Robert J Motzer
JAMA Oncology|October 28, 2016
Perioperative Management of Localized Kidney Cancer: Watching and WaitingMartin H Voss, Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easyGeorge J Bosl, Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Targeting renal cell carcinomaRobert J Motzer, Ana M Molina
The Urologic Clinics of North America|November 11, 2008
Systemic therapy for metastatic renal cell carcinomaGlenn S Kroog, Robert J Motzer
World Journal of Urology|June 11, 2009
Good-risk-advanced germ cell tumors: historical perspective and current standards of careDarren R Feldman, Robert J Motzer
Pageof 44

Showing results (11-20 of 436) with videos related to

Sort By:
Pageof 44
Cancer Journal (Sudbury, Mass.)|April 26, 2016
Immune Checkpoint Therapy in Renal Cell CarcinomaChung-Han Lee, Robert J Motzer
Urologic Oncology|December 4, 2014
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinomaChung-Han Lee, Robert J Motzer
Nature Reviews. Nephrology|January 20, 2017
Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancerChung-Han Lee, Robert J Motzer
The New England Journal of Medicine|April 17, 2024
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New ChallengesMartin H Voss, Robert J Motzer
Seminars in Urologic Oncology|December 19, 2002
Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumorsG Varuni Kondagunta, Robert J Motzer
JAMA Oncology|October 28, 2016
Perioperative Management of Localized Kidney Cancer: Watching and WaitingMartin H Voss, Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easyGeorge J Bosl, Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Targeting renal cell carcinomaRobert J Motzer, Ana M Molina
The Urologic Clinics of North America|November 11, 2008
Systemic therapy for metastatic renal cell carcinomaGlenn S Kroog, Robert J Motzer
World Journal of Urology|June 11, 2009
Good-risk-advanced germ cell tumors: historical perspective and current standards of careDarren R Feldman, Robert J Motzer
Pageof 44